Compare ALCO & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | SGHT |
|---|---|---|
| Founded | 1960 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 193.2M |
| IPO Year | N/A | 2021 |
| Metric | ALCO | SGHT |
|---|---|---|
| Price | $37.22 | $8.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.66 |
| AVG Volume (30 Days) | 28.4K | ★ 180.1K |
| Earning Date | 11-24-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $44,066,000.00 | ★ $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.76 | $2.03 |
| 52 Week High | $37.90 | $8.80 |
| Indicator | ALCO | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 67.10 | 60.36 |
| Support Level | $36.07 | $8.22 |
| Resistance Level | $37.90 | $8.63 |
| Average True Range (ATR) | 0.96 | 0.51 |
| MACD | 0.32 | -0.10 |
| Stochastic Oscillator | 95.33 | 58.85 |
Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.